{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T17:47:49Z","timestamp":1776448069647,"version":"3.51.2"},"reference-count":0,"publisher":"American Medical Association (AMA)","issue":"14","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA"],"published-print":{"date-parts":[[2023,4,11]]},"DOI":"10.1001\/jama.2023.4003","type":"journal-article","created":{"date-parts":[[2023,3,22]],"date-time":"2023-03-22T15:02:41Z","timestamp":1679497361000},"page":"1142","source":"Crossref","is-referenced-by-count":17,"title":["Trofinetide Receives FDA Approval as First Drug for Rett Syndrome"],"prefix":"10.1001","volume":"329","author":[{"given":"Emily","family":"Harris","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"10","container-title":["JAMA"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jama\/articlepdf\/2802886\/jama_harris_2023_ib_230081_1680895640.5194.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,11]],"date-time":"2023-04-11T15:08:14Z","timestamp":1681225694000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jama\/fullarticle\/2802886"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,11]]},"references-count":0,"journal-issue":{"issue":"14","published-print":{"date-parts":[[2023,4,11]]}},"URL":"https:\/\/doi.org\/10.1001\/jama.2023.4003","relation":{},"ISSN":["0098-7484"],"issn-type":[{"value":"0098-7484","type":"print"}],"subject":[],"published":{"date-parts":[[2023,4,11]]}}}